Search research articles
Contact Us
Filters
Showing results (151-160 of 173) with videos related to
Page
of 18
Sort By:
Annals of the New York Academy of Sciences
|
May 7, 2009
Structure and activity in the relaxin family of peptides
Geoffrey W Tregear, Ross A D Bathgate, Mohammed Akhter Hossain, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 10, 2021
In Aged Females, the Enhanced Pressor Response to Angiotensin II Is Attenuated By Estrogen Replacement via an Angiotensin Type 2 Receptor-Mediated Mechanism
Giannie Barsha, Katrina M Mirabito Colafella, Sarah L Walton, et al.
Kidney International
|
January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
Bryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 9, 2002
Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis
Chrishan S Samuel, Chongxin Zhao, Ross A D Bathgate, et al.
Journal of Medicinal Chemistry
|
January 20, 2012
Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1
Fazel Shabanpoor, Mohammad Akhter Hossain, Philip J Ryan, et al.
Endocrinology
|
August 29, 2006
The effects of relaxin and estrogen deficiency on collagen deposition and hypertrophy of nonreproductive organs
Edna D Lekgabe, Simon G Royce, Tim D Hewitson, et al.
JACC. Clinical Electrophysiology
|
February 28, 2021
Atrial Fibrillation and Obesity: Reverse Remodeling of Atrial Substrate With Weight Reduction
Rajiv Mahajan, Dennis H Lau, Anthony G Brooks, et al.
Scientific Reports
|
June 9, 2017
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1
Martina Kocan, Mohsin Sarwar, Sheng Y Ang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 3, 2023
Novel AT<sub>2</sub>R agonist, β-Pro<sup>7</sup>Ang III, is cardio- and vaso-protective in diabetic spontaneously hypertensive rats
Mandy Li, Levi Nguyen, Dorota Ferens, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
February 8, 2023
The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy
Fariha Alam, Tracey A Gaspari, Barbara K Kemp-Harper, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 173) with videos related to
Sort By:
Page
of 18
Annals of the New York Academy of Sciences
|
May 7, 2009
Structure and activity in the relaxin family of peptides
Geoffrey W Tregear, Ross A D Bathgate, Mohammed Akhter Hossain, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 10, 2021
In Aged Females, the Enhanced Pressor Response to Angiotensin II Is Attenuated By Estrogen Replacement via an Angiotensin Type 2 Receptor-Mediated Mechanism
Giannie Barsha, Katrina M Mirabito Colafella, Sarah L Walton, et al.
Kidney International
|
January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
Bryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 9, 2002
Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis
Chrishan S Samuel, Chongxin Zhao, Ross A D Bathgate, et al.
Journal of Medicinal Chemistry
|
January 20, 2012
Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1
Fazel Shabanpoor, Mohammad Akhter Hossain, Philip J Ryan, et al.
Endocrinology
|
August 29, 2006
The effects of relaxin and estrogen deficiency on collagen deposition and hypertrophy of nonreproductive organs
Edna D Lekgabe, Simon G Royce, Tim D Hewitson, et al.
JACC. Clinical Electrophysiology
|
February 28, 2021
Atrial Fibrillation and Obesity: Reverse Remodeling of Atrial Substrate With Weight Reduction
Rajiv Mahajan, Dennis H Lau, Anthony G Brooks, et al.
Scientific Reports
|
June 9, 2017
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1
Martina Kocan, Mohsin Sarwar, Sheng Y Ang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
August 3, 2023
Novel AT<sub>2</sub>R agonist, β-Pro<sup>7</sup>Ang III, is cardio- and vaso-protective in diabetic spontaneously hypertensive rats
Mandy Li, Levi Nguyen, Dorota Ferens, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
February 8, 2023
The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy
Fariha Alam, Tracey A Gaspari, Barbara K Kemp-Harper, et al.
Page
of 18